Nulojix - direct healthcare professional communication (DHPC)

belatacept

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC): Nulojix (belatacept): Risk of medication errors due to change in maintenance dose from 5 mg/kg to 6 mg/kg

Dissemination date: 12/09/2022

Key facts

• Medicine name:
  Nulojix
• Active substance:
  belatacept
• Therapeutic area (MeSH):
  • Graft Rejection
  • Kidney Transplantation
• Procedure number:
  EMEA/H/C/002098/II/0079/G
• Regulatory outcome:
  Maintenance
• DHPC type:
  Medication error
• Human ATC codes:
  L04AA28
• Dissemination date:
  12/09/2022